We have had another successful quarter and are working hard to finish the year strong. We’re excited to announce that we’ve moved into our new headquarters on the Broadwest campus in the Vanderbilt/West End corridor of Nashville. This move allows us to continue collaborating with Vanderbilt University Medical Center and will accommodate our anticipated growth.

Highlights from the third quarter include:

• We largely completed the transition of Sancuso® to Cumberland from Japan-based Kyowa Kirin following our acquisition of the brand in January. Sancuso is an FDAapproved prescription patch that prevents nausea and vomiting in patients undergoing certain types of chemotherapy. We have assumed responsibilities for its sales, distribution and promotion in the U.S.

• We entered into an agreement with PiSA Pharmaceutical, giving them exclusive supply and distribution of Caldolor® – our ibuprofen injection product – in Mexico. Under the agreement, PiSA will be responsible for obtaining regulatory approval and commercializing the product in Mexico.

• We continue to work on our series of Phase II clinical trials – focusing on ifetroban for patients with a series of unmet medical conditions and needs. We are looking forward to sharing results from our studies and continuing the development of ifetroban.

A special thanks to everyone involved in our corporate move, and to the entire Cumberland team for their dedication and many contributions that led to such a successful third quarter. We remain sharply focused on our mission of improving patient care through the delivery of high-quality medicines and look forward to providing another update after the new year.